Gesundheitszentrum Hoppegarten
- Address
- Lindenallee 7, 15366 Hoppegarten, Germany
Gesundheitszentrum Hoppegarten - Migraine Research Center
Gesundheitszentrum Hoppegarten is a specialized clinical research facility dedicated to advancing the understanding and treatment of neurological conditions, with a particular focus on migraine disorders. The center participates in pivotal studies evaluating novel therapeutic approaches for migraine prevention and management in adult populations.
- Comparative efficacy and safety studies of migraine preventive medications
- Chronic and episodic migraine treatment optimization
- Tolerability assessments of emerging oral therapies for migraine prevention
The research team at Gesundheitszentrum Hoppegarten has extensive experience in conducting large-scale, comparative clinical trials that evaluate both traditional and novel preventive treatments for migraine. Their participation in the TEMPLE study demonstrates their commitment to identifying therapeutic options that balance efficacy with improved tolerability profiles, ultimately aiming to enhance quality of life for patients suffering from both chronic and episodic forms of migraine.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Gesundheitszentrum Hoppegarten
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Randomized, Double-blind, Parallel-group, Active Controlled Trial with Open-label Safety Extension to Evaluate the Tolerability, Safety, and Efficacy of Atogepant versus Topiramate in Subjects Requiring Preventive Treatment of Migraine (TEMPLE) | AbbVie Deutschland GmbH & Co. KG | Phase III | Not Recruiting | Jan 2024 | May 2026 |
IMP list
lock Showing 1 of 2 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Atogepant | 1 | Unknown | 2024-01-17 | 2024-01-17 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.